Immunity to Immunotherapy in Cancer
Mechanisms and Limitations
- 1st Edition - April 22, 2026
- Latest edition
- Editors: Mukesh Nandave, Deepa Mandlik
- Language: English
Immunity to Immunotherapy in Cancer: Mechanisms and Limitations explores the intricate interplay between cancer therapy and the immune system, addressing why some patients do not… Read more
Description
Description
Designed as a comprehensive guide for professionals and researchers, this textbook offers an overview of the latest scientific discoveries and practical applications in cancer therapy. It serves as an invaluable resource for scientists, doctors, academicians, and students, presenting a path toward more effective, non-toxic, and customized cancer treatments. This book is essential for anyone interested in the future of cancer therapy.
Key features
Key features
- Provides an in-depth examination of the molecular strategies of immune evasion and the tumor microenvironment, offering critical insights into why some patients do not respond to immunotherapy
- Bridges the gap between current research and practical therapeutic applications in cancer immunotherapy
- Highlights the latest advancements in cancer therapy, discussing cutting-edge strategies such as combination therapies, personalized medicine, and novel immunotherapeutic agents
Readership
Readership
Table of contents
Table of contents
1. Introduction to Immunity in Cancer
2. Role of Innate Immunity in Cancer Immunology
3. Role of Dendritic Cells in Cancer Immunology
4. Role of Natural Killer Cells in Cancer Immunology
5. Role of B-Cells in Tumor Immunity
6. Role of CD4+ T-Cells in Cancer Immunology
7. Role of Regulatory T-Cells and Th17 Cells in Tumor Microenvironment
8. Role of Monocytes, Macrophages, and Polymorphonuclear Cells in Cancer Immunology
9. Role of Cytokines in Cancer Immunology
10. Role of Chemokines and Chemokine Receptors in Cancer Immunology
11. Role of the Inflammasome in Cancer Immunology
12. Current Advanced Immunological Tools and Databases in Tumor Immunity
13. Tumor Heterogeneity and Therapeutic Resistance
Part B: Cancer Immunotherapy
14. Cancer Immunotherapy: Pros, Cons, and Beyond
15. Role of Monoclonal Antibody, Immune Checkpoint Inhibitors, and Programmed Death Ligand 1 in Cancer Immunotherapy
16. Role of Chimeric Antigen Receptor-T Cell in Cancer Immunotherapy
17. Role of Small Molecule-Based Drugs in Cancer Immunotherapy
18. Role of Adoptive Cell Therapy in Cancer Immunotherapy
19. Role of Cancer Vaccines in Cancer Immunotherapy
20. Role of Radiotherapy/Chemotherapy in Cancer Immunotherapy
Product details
Product details
- Edition: 1
- Latest edition
- Published: April 24, 2026
- Language: English
About the editors
About the editors
MN
Mukesh Nandave
DM
Deepa Mandlik
Dr. Deepa Mandlik is an Associate Professor at Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy, Pune. She brings extensive teaching and research experience across her career and has demonstrated outstanding academic achievement in her early training. She has published extensively in reputable national and international journals and has authored several pharmaceutical books along with multiple international book chapters. A recognized PhD guide, she mentors doctoral researchers and oversees a active cohort of postgraduate students. She is a life member of APTI and a member of CRS-Indian Chapter. Her research interests encompass nanotechnology, targeted drug delivery, quality by design, design of experiments, and optimization techniques, reflecting a strong commitment to innovation in pharmaceutical science. Dr. Mandlik is known for integrating rigorous scientific inquiry with teaching and mentorship to advance the development of the next generation of pharmaceutical researchers.